Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences (WVE) today and set a price target of $65. The company’s shares opened today at $43.41.
According to TipRanks.com, Syed is a 4-star analyst with an average return of 5.3% and a 60.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Gilead Sciences, and Biogen Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wave Life Sciences with a $63 average price target.
See today’s analyst top recommended stocks >>
Based on Wave Life Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $37.63 million. In comparison, last year the company had a GAAP net loss of $30.21 million.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
